Background {#Sec1}
==========

Asthma and chronic obstructive pulmonary disease (COPD) are frequent in the general population. The prevalence of asthma is estimated to be between 1 and 18 % of the population in the countries where it has been studied \[[@CR1]\], whereas COPD affects about 6 % of the adult population, with a higher prevalence in older age groups \[[@CR2]\]. These diseases are characterised by a narrowing of the bronchi associated with chronic inflammation. However, there are some differences between asthma and COPD in terms of onset age, causal factors, clinical aspects and impact on daily life. Functional measurements are used to measure severity and reversibility of the pulmonary obstruction. However, the relationship between pulmonary obstruction, dyspnea and impact of the disease on the daily life of the patient, is not necessarily linear \[[@CR3]\]. The subjective data obtained from the patients can be useful for supplementing clinical and instrumental data and enabling the physician to identify any change (improvements or worsening) in the state of health, as perceived by the patient, thus allowing for an adjustment of the treatment. Questionnaires do exist and have been used for decades as they can gather data, in a standardised form, about the patients' perception of the status of the disease and/or the received medical treatments. This information, reported directly by the patient without other people's interpretation, about his/her well-being, behaviour and feelings as regards his/her state of health and the related treatments, is defined as Patient-Reported Outcome (PRO) \[[@CR4]\]. The Health-related Quality of Life (HRQoL) is a well known PRO. We have had available for some time questionnaires that are used for measuring HRQoL. European and USA regulatory authorities have published official guidance documents that reflect their position on this topic. The USA Food and Drug Administration (FDA) prepared a formal "Guidance for Industry" which describes its position on the PROs and informs the pharmaceutical industry on how it intends to review and evaluate the PRO tools that are used to support label claims \[[@CR5]\]. The European Medicine Agency (EMA) document points out the role that the HRQoL may play in the development process of a medicinal product, by simply providing some recommendations on their use \[[@CR6]\]. Recently, a number of new medicinal products to be used alone or in fixed combinations have been registered for the treatment of asthma and/or COPD. In many clinical studies of these drugs, HRQoL measurements were included.

Our aim was to deepen the knowledge on how the measurement of HRQoL was carried out for supporting the registration of these drugs (medicinal products of chemical and not biological origin). We planned to review the papers in order to describe and comment on the used tools, the results of the measurements and the use of the HRQoL data that were obtained. We had no intention to comment on the degree of efficacy of the medicinal products being considered.

Review {#Sec2}
======

We took into consideration the respiratory drugs that were launched in the last years. We described randomised and controlled clinical trials of medicinal products developed for asthma and for COPD, published from 2009 to the spring of 2014. The year 2009 was chosen because in that year the National Health Service in England (NHS) made the decision to measure the impact, as perceived by the patient, of some therapeutic procedures \[[@CR7]\]. Non-randomised studies, *post-hoc*analyses, meta-analyses and/or systematic reviews of respiratory medicinal products have not been taken into account. For each study, the design, sample size, use of tools for the measurement of PROs have been identified and the related data briefly described. No statistical analyses of any type were carried out; in fact this report consists exclusively in a description of the findings.

Thirty four articles, published in the considered period, were analysed (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Eleven studies were on asthma. The questionnaire used in these studies was the Asthma Quality of Life questionnaire (AQLQ). The AQLQ is a 32 items questionnaire in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). It is suitable for adult with asthma, that should respond on a 7 point scale. Psychometric tests show that a change in score of 0.5 is the smallest change that can be considered clinically important (this means that the patient appreciates the change in his/her health condition).Table 1Studies on asthmaDrugsBaselineFinal scoreStatistical significance^a^Clinical significanceReferenceflut/form 500/20 μg4.42 ± 0.895.34 ± 1.07*P* = 0.036Bodzenta-Lukaszyk et al. Resp Med 105 674-682 2011 \[[@CR13]\]flut + form 500 + 24 μg4.57 ± 0.995.30 ± 1.00flut/form250/10 μgNot reportedMean improvement of 0.8 in both treatment groupsns55 %Bodzenta-Lukaszyk et a.l Journal of Asthma 49(10), 1060-1070, 2012 \[[@CR14]\]bud/form400/12 μg57.6 % nsflut/form combo4.8 ± 1.15.5 ± 1.1nsNot availableBodzenta-Lukaszyk et al. Current Medical Research and Opinion 29, 5 579-588, 2013 \[[@CR15]\]flut + form4.9 ± 1.25.6 ± 1.0Tio 5 μg add on4.8 in all groupsChange of 0.1 points for both active treatments compared with placebonsNot availableKerstjens et al. Journal of Allergy Clin Immunol 128, 2 308-314, 2011 \[[@CR16]\]Tio 10 μg add onPlac add onTrial 1Not achievedKerstjens et al. New England Journal of Medicine 367:1198-1207, 2012 \[[@CR17]\]Tio 5 μg/die add on4.6 ± 1.15.15Nsplac add on4.6 ± 1.15.1Ns (*p* \< 0.05 al week 24Trial 2Tio 5 μg/die add on4.6 ± 1.05.1plac add on4.7 ± 1.14.93Bud/formSMART4.784.81nsNot available -- measurement of Satisfaction with Asthma Treatment QuestionnaireLouis R et al. The International Journal of Clinical Practice 63, 10 1479-1488, 2009 \[[@CR18]\]Conventional best practice4.784.82Tio5.58*P* = 0.01Not availablePeters et al. New England Journal of Medicine 363 18 1715-1726, 2010 \[[@CR19]\]Double glucocorticoid5.43 ± 1.055.48*P* = 0.38salm5.71*P* \< 0.001Flut fur/vil 200/25 μgNot availableBaseline + 0.93 ± 0.065nsNot availableO'Byrne et al. Eur. Resp. Journal 43 773-782, 2014 \[[@CR20]\]Flut fur.200 μgBaseline + 0.88 ± 0.071Flut prop.500 μgBaseline + 0.90 ± 0.068Flut. fur/vil 100/25 μg5.355.85ns46 %Woodcock et al. Chest 144(4), 1222-1229, 2013 \[[@CR21]\]flut. pro/salm 250/50 μg5.375.7938 %salm 50 μg5.175Baseline + 0.280nsNot availableBateman et al. J. Allergy Clin Immunol128, 315-322, 2011 \[[@CR22]\]tio 5 μgBaseline + 0.131placBaseline + 0.039Not availableAdjustable bud/formAQLQAQLQAQLQAQLQO'Connor et al. Journal of Asthma 47 217-223, 2010 \[[@CR10]\]Fixed bud/formNot availableNot available*P* \< 0.04\*66.7 %Adjustable bud/formNs^b^63.0 %61.9 %No clinical difference between groups^a^Between groups^b^Fixed-dose regimen baseline vs end of treatment\*Adjustable dosing vs fixed dose regimen*p* ≤ 0.002 vs fluticasone propionate/salmeterolTable 2Studies on COPDDrugsBaseline SGRQFinal scoreStatistical significance^a^Clinical significanceReferenceAclid 200 μg45.9-4.7 vs baseline*P* = 0.013 vs plac.49 %\*Kerwin E.M., et al. *COPD patients (ACCORD COPD I).* COPD 9 90-101, 2012 \[[@CR23]\]Aclid 400 μg48.3-4.5 vs baseline*P* = 0.019 vs plac.45 %plac45.1- 2 vs baseline36 %Aclid 200 μg46.3 ± 16.8.-3.8 ± 1.1 vs plac*P* \< 0.001vs plac56.0 %\*\*Jones P.W., et al. Eur Resp Journal 40 830-836, 2012 \[[@CR11]\]Aclid 400 μg47.6 ± 17.7-4.6 ± 1.1*P* \< 0.0001 vs57.3 %\*\*plac45.1 ± 15.8plac.41.0 %Aclid 200 μg48.5-5.3 vs baselinens41-6 % - 46.6 %Gelb A.F., et al. Respiratory Medicine 107 1957-1965, 2013 \[[@CR24]\]Aclid 400 μg49.8-5.2 vs baseline45.2 % - 49.1 %Glycopyr 50 μg46.1139.50*P* = 0.00456.8 %D'Urzo A., et al. Respiratory Research 12 156, 2011 \[[@CR25]\]Plac46.3442.3146.3 %*P* = 0.006Glycopyr 50 μgNot-3.32 vs placebo*P* \< 0.00154.3 %Kerwin E., at al. European Respiratory Journal 40 1106-1114, 2012 \[[@CR26]\]Tio 18 μgreported-2.84 vs placebo*P* = 0.01459.4 %Plac50.8 %Indac 300 μg43-4.7 vs placebo*P* \< 0.001 vs placNot reportedDahl R. et al. Thorax 65 473-479, 2010 \[[@CR27]\]Indac 600 μg44-4.6 vs placeboForm44-4.0 vs placeboPlac43Indac 150 μg43 ± 18.6-5.0 vs baseline*P* \< 0.00152.8 %\*\*Kornmann O. et al. European Respiratory Journal 37 273-279, 2011 \[[@CR28]\]Salm 50 μg44. ± 18.4-4.1 vs baseline*P* \< 0.00148.6 %\*\*\*plac44 ± 18.138.0 %Indac 150 μgNot reported-3.3 vs placebo\*\*\*\**P* \< 0.001 vs plac-Donohue J.F. et al. Am J Respir Crit Care Med 182 155-162, 2010 \[[@CR29]\]Indac 300 μg-2.4 vs placebo*P* \< 0.01 vs placTio 18 μg-1.0 vs placeboNs vs placplacIndac 150 μg42.3 ± 17.6037.1 ± 0.56*P* \< 0.00150.5 %Buhl R. et al. Eur Respir J 38 797-803, 2011 \[[@CR30]\]Tio 18 μg42.7 ± 18.0439.2 ± 0.5542.5 %p ≤ 0.001Indac 150 μg47.942.3*P* = 0.7349 %Decramer M.L. et al. Lancet Respir Med 1 524-533, 2013 \[[@CR31]\]Tio 18 μg48.742.249 &Tio 5 μgNot reported-4.7 vs baseline*P* \< 0.000149.5 %Bateman E.D. et al. Respiratory Medicine 104, 1460-1472, 2010 \[[@CR32]\]P lac-1.8 vs baseline41.4 %*P* \< 0.0001Tio 18 μg emphysema46.7 ± 3.039.4 ± 2.7nsNot reportedFujimoto K. et al. International Journal of COPD 6, 219-227, 2011 \[[@CR33]\]Tio 18 μg non emphys35.1 ± 6.426.9 ± 4.6Salm 50 μg emphysema38.6 ± 3.533.0 ± 3.2Salm 50 μg nonemphys37.5 ± 8.529.3 ± 7.4Tio 18 μg46.1 ± 19.1-4.5 vs baseline*P* \< 0.05Not reportedHoshino M. et al Respirology 16 95-101, 2011 \[[@CR34]\]Tio + Salm/flut 50/250 μg42.7 ± 17.0-10.2 vs baselineUmec 62.5 μgNot reported-3.14 vs baseline*P* \< 0.001 both doses of umeclidinium vs placeboNot reportedTrivedi R. et al. Eur Respiratory J 43 72-81, 2014 \[[@CR35]\]Umec 125 μg-6.12 vs baselinePlac+4.75 vs baselineBeclom/form 100/6 μg60.4 ± 19.5-3.75 ± 13.91ns25.40 %Calverley P.M.A. et al*.*Respiratory Medicine 104 1858-1868, 2010 \[[@CR36]\]Bud/form 200/6 μg57.2 ± 18.6-4.28 ± 11.9221.90 %Form 12 μg59.5 ± 20.2-2.90 ± 13.2825.30 %Tio + bud/formNot reported-3.8 vs baseline*P* = 0.02349.5 %Welte T. et al. Am J Respir Crit Care Med 180 741-750, 2009 \[[@CR37]\]Tio + plac-1.5 vs baseline40.0 %*P* = 0.016Bud/form 320/9 μg55.9 (17.6)-7.2 (1.18) vs bas.nsSharafkhaneh A. et al. Respiratory Medicine 106, 2257-268 2012 \[[@CR38]\]Bud/form 160/9 μg57.8 (16.7)-5.5 (1.17) vs bas.Form 9 μg58.6 (16.9)-5.9 (1.17) vs bas.Indac/Glycopyr 110/50 μg42.0135.45ns55.5 %Vogelmeier C.F. et al. Lancet Respir Med 1 51-60, 2013 \[[@CR39]\]Salm/flut 50/500 μg42.7236.6849.1 %Indat/Glycopyr 110/50 μg53 (18)43.8glycop/indacat57 %Wedzicha J.A. et al. Lancet Respir Med 1 199-209, 2013 \[[@CR40]\]Glycopyr 50 μg52 (18)45.8*P* = 0.0067 e52 %Tio 18 μg52 (17)46.0*P* = 0.00037 vs competitors51 %Glycopir/indacat *p* = 0.055 e *p* = 0.051 vs competitorsIndac 150 μg + Glycopyr 50 μgNot reported- 6.22 (11.47)ns56.5 %Vincken W. et al. Int Journal of COPD 9 215-228, 2014 \[[@CR41]\]Indac 150 μg- 4.13 (10.38) vs baseline46.8 % nsBeclom/form 200/12 μg47.0 (16.7)-5.92*P* = 0.0845.0 %Singh D. et al. BMC Pulmonary Medicine 14 43 2014 \[[@CR42]\]Flutic/salm 500/50 μg45.2 (16.5)-3.8036.2 %nsUmec/Vil 62.5/25 μgNot reported-8.07 (0.749)p ≤ 0.001 vs49 %Donohue J.F. et al. Respiratory Medicine 107 1538-1546, 2013 \[[@CR43]\]Umec 62.5 μg-7.25 (0.753)placebo44 %Vil25 μg-7.75 (0.760)48 %Plac-2.56 (0.950) vs baseline34 %Umec/Vil125/25 μgNot reported40.10 (0.665)Combination49 %Celli B. et al Chest 145 (5) 981-991, 2014 \[[@CR44]\]Umec125 μg43.38 (0.664)p ≤ 0.001 vs umec e40 %Vil 25 μg42.82 (0.681)*p* \<0.01 vs41 %Plac43.69 (0.875)vilanterol37 %^a^Between groups\**p* \< 0.005 vs placebo\*\**p* \< 0.001 vs placebo\*\*\**p* \< 0.01\*\*\*\**p* \< 0.01 vs tiotropium

Twenty three studies were on COPD. The questionnaire they used was the Saint George\'s Respiratory Questionnaire (SGRQ). It is a 50 items questionnaire designed to measure impact on overall health, daily life and perceived well-being in patients with COPD. Higher scores indicate more limitations. A mean change score of −4 units is considered as clinically important.

Only 3 studies on asthma reported a change that was statistically significant (27 % of the studies), and only 2 (18 % of the studies) reported the percentage of patients who reached the clinical significance (at least 0.5 change from baseline). The clinical significance ranged between 55.0 and 66.7 % of patients. Among studies on COPD, 16 (69.5 %) reported a statistical significance and 17 (80 %) reported the percentage of patients with the clinical significance (at least −4 units from baseline). The clinical significance ranged between 21.9 and 59.4 % of patients.

Usually, the authors describe in a very short way HRQoL results, and poor details are reported.

Conclusions {#Sec3}
===========

A description of the literature about respiratory, non-biological medicinal products, developed in the past few years, has allowed to highlight that the PRO measurement has been often included in the studies' protocols. This is in line with the recognition by regulatory authorities, payers and pharmaceutical companies that measurement of the patient experience with the drug is increasingly important. In all the measurements observed, the subjective data was considered a secondary endpoint. This is consistent with the endpoint hierarchy established by EMA and the FDA which sees the physiological effect produced by the study drug as a priority, and relegates the PRO to a secondary endpoint.

The choice of tools to be used meets the specifications of the reference documents. AQLQ is used with the patients with asthma, whereas the SGRQ is used with the patients with COPD. Both tools have been well documented since their initial development, and are validated and available in many languages \[[@CR8], [@CR9]\]. In all the studies, the time frame for the administration of the questionnaires is specified. In the shorter studies, the measurements are reported at the baseline and at the end of the study. In longer studies, there can be interim measurements. It should be noted that the short duration of a study (in particular in the COPD case) is planned to allow for functional measurements, but it could not capture the impact that the drug has on the health, as perceived by the patient. For instance, Kerwin reports, in the conclusions of his study, that a duration above 12 weeks could have allowed the patients treated with aclidinium 400 μg to reach the Minimal Clinical Important Difference (MCID) in a significantly greater percentage compared with the patients receiving placebo \[[@CR10]\]. A further aspect for consideration is the use of the placebo treatment arm. These patients may receive rescue treatment, and often the variation in the SGRQ score obtained with these patients is important, as is the percentage of responder patients (those who reach the MCID). Another aspect noted in some studies was that the improvement reported with the SGRQ was in contrast with the bronchodilator effect. For example, Jones et al point out this aspect in the placebo arm of their study where the spirometry values decline, but the patients report a better respiratory state of health \[[@CR11]\].

The measurements are always accompanied by information on their statistical significance. With reference to this point, we noted that more COPD than asthma studies reported a statistical significance. In other words, it seems that COPD drugs are significantly more effective than asthma drugs. Furthermore, it is to consider that a number of COPD studies foresaw the analysis versus a placebo arm, and the number of patients could be excessive for the HRQoL measurement. With reference to the clinical significance, asthma patients have a higher percentage of patients who experienced a clinically important change than COPD patients (despite the lower number of measurements). We can speculate that asthma patients perceive better the changes given by drugs than COPD patients. On the other hand, asthmatics are generally younger than COPD patients, and suffer less from other diseases (comorbidities). However, the subjective nature of the measurements should lead to some considerations on the significance of the effects produced by the treatment. Usually, the variations in the scores obtained from the questionnaires on HRQoL are assessed on an effect-size basis, since a change produced by a treatment may be statistically significant (possibly because the number of patients calculated for the main endpoint is high), but it may not be perceived as clinically significant by the patients. In general, effect-size indexes have been developed for the exact purpose to avoid making incorrect inferences, due also to high sample sizes. In other words, since the above indicated indexes seek to square the results net of the effects of the sample (number of subjects), they should not be affected by this data. The effect-size indexes allow for an evaluation of the amplitude of an effect in each research design, but there always remains the difficulty of choosing the most appropriate index and interpreting the results. Perhaps the latter is the reason why measurement results are usually reported without comments. In some cases, PRO measurement data are included in the discussion, but in many other cases, they are only briefly mentioned.

Undoubtedly, the PRO adds knowledge to the drug. Within the respiratory area, there are many medicinal products available which have demonstrated their efficacy in intervening on the two main characteristics that define asthma and COPD, i.e. bronchoconstriction and chronic inflammation. However, only some of them provide information about the outcomes of treatment which may be important to patients. This data could represent a discriminatory factor in the choice of the medicinal products to be included into a formulary. In fact, a medicinal product that is perceived as useful by the patient could have more probability to be taken (good adherence to treatment) and this would maximise the financial investment of the third party payer. Among the cited studies, one has used the Onset of Effect Questionnaire (OEQ) to measure the preference of the patient with asthma of a certain bronchodilator versus another bronchodilator in the same pharmacological category, but slower in manifesting its effects \[[@CR10]\]. The fact that this questionnaire was not used in other studies may mean that it is not important to measure this parameter, or that the questionnaire was used in that study just to reiterate that one of the drugs was faster in manifesting its effects.

Some studies, not included in this analysis because they were published before 2009, measured the preferences of the patients regarding the inhaler used. Dalby et al cite these experiences in one article that discusses the development of an inhaler \[[@CR12]\]. This measurement can be useful also if the intent is to provide the patient with a treatment, that, on average, he/she will consider satisfactory and therefore, presumably, be more willing to adopt.

To conclude, the subjective measurements, initially reserved for patients with very serious diseases and a limited life expectancy, have become more commonly used even with patients suffering from chronic diseases. The fact that patients with asthma and COPD can have a longer life expectancy makes the quality of those years left to live very important. It is therefore desirable that the PRO measurements be increasingly used and become part of the daily routine of clinical practice. In this perspective, tools such as the SGRQs might be considered labour-intensive requiring too long for their completion and interpretation. To this end, some other easier and simpler tools could be proposed for development.
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:   Asthma Quality of Life questionnaire
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:   chronic obstructive pulmonary disease
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:   onset of effect questionnaire
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:   patient-reported outcome

SGRQ
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